fda approval of frontline osimertinib in frontline egfr-mutant nsclc
Published 6 years ago • 218 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
3:14
dr. west on fda approval of frontline osimertinib in egfr nsclc
-
0:40
copy of dr. west on fda approval of frontline osimertinib in egfr nsclc
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
5:18
frontline therapy for egfr plus nsclc: osimertinib’s impact
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
8:11
advances in frontline therapy for egfr nsclc
-
5:31
fda approval: frontline ceritinib for alk nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
6:01
fda d.i.s.c.o.: osimertinib for non-small cell lung cancer
-
1:45
phase iii data support frontline osimertinib in egfr-mutant lung cancers
-
1:36
comment: front-line osimertinib significantly lengthens overall survival in egfr-mutation positi...
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
1:54
dr. wakelee on fda approval of frontline pembrolizumab in nsclc
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
0:55
dr. west on fda approval of frontline alectinib in alk nsclc
-
3:42
fda approves osimertinib as adjuvant therapy for non-small cell lung cancer with egfr mutations